ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PRGO vs PVLA // EV/EBITDA & P/E VALUATION

Perrigo Company plc (NYSE) VS. Palvella Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PRGO 5 — PVLA 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRGO VS. PVLA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PRGO PVLA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 35.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -13.60% -27.90% +14.30 PRGO /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield 6.58% -1.14% +7.72 PRGO /fcf-yield <GO>
Operating Margin -26.40% — — TIE /operating-margins <GO>
Net Profit Margin -33.50% — — TIE /net-margins <GO>
Revenue Growth (YoY) -2.80% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 7.22% 0.00% +7.22 PRGO /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 2/9 +3.00 PRGO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 55.3 59.5 -4.30 PVLA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.21B $2.18B $22.4M PRGO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PRGO REV PVLA REV PRGO GROSS % PVLA GROSS % PRGO FCF PVLA FCF
FY 2025 $4.25B $0 35.1% — $145.1M -$25.0M
FY 2024 $4.37B $0 35.3% — $244.6M -$10.8M
FY 2023 $4.66B $42.8M — — $405.5M -$13.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRGO // BETA —
PVLA // BETA —